Phase 2 trial reveals potential of DPP-1 inhibitor for bronchiectasis
The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...
Medical Dialogues1d
3D Imaging-Assisted Segmentectomy effective treatment for Localized Bronchiectasis: Study
Surgery is essential for the effective management of bronchiectasis. Segmentectomy, while a challenging procedure, has become ...
The Manila Times3d
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
"We are pleased that Oaktree and OMERS recognize the ongoing success of the Ohtuvayre™ (ensifentrine) launch and continued ...
Vast Granted Qualified Infectious Disease Product Designation from the FDA
Vast Therapeutics, a clinical-stage life science company, today announced that the U.S. Food and Drug Administration has ...
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
The Lancet6d
Targeting neutrophil serine proteases in bronchiectasis—where are we now?
Over the past decades, bronchiectasis has been neglected, despite the global burden.1,2 To date, better diagnosis due to easy ...